Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | TK2 | O00142 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13944237 | 0.89 | TK1 (0.42) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL4176430 | 0.88 | TK1 (0.69) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL4176433 | 0.88 | TK1 (0.69) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL610031 | 0.87 | LMNA (0.56) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL601434 | 0.87 | LMNA (0.56) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL601433 | 0.87 | LMNA (0.56) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL13944236 | 0.87 | LMNA (0.56) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL2041365 | 0.82 | LMNA (0.58) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL2041364 | 0.82 | LMNA (0.58) | TK1LMNASMN1; SMN2ALOX12ADRA1A | |
| SCHEMBL2026926 | 0.82 | TK1 (0.76) | TK1LMNASMN1; SMN2ALOX12ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090004137-A1 | Uridine Derivatives as Antiviral Drugs Against a Flaviviridae, Especially Hcv | INSTITUTE NATIONAL DE LA SAINTE ET DE LA RECHDERCHE MEDICALE (FR) | 2009-01-01 | — | — | US | disclosed |
| EP-1674104-A1 | Uridine derivatives as antiviral drugs against a flaviviridae, especially HCV | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2006-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090004137-A1 | Uridine Derivatives as Antiviral Drugs Against a Flaviviridae, Especially Hcv | NUDT1, UMPS, UPP1 | TK1 206/4885LMNA 4072/4885SMN1; SMN2 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.